{"schema_version":"secwatch.filing_event.v1","accession":"0001842952-24-000005","form_type":"8-K","ticker":"CNTX","cik":"0001842952","company_name":"Context Therapeutics Inc.","filed_at":"2024-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.931885+00:00","generated_at":"2026-06-05T02:55:22.023851+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Context Therapeutics amends Integral license for CTIM-76 after finding potential third-party patent conflict","bullets":["Discovered third-party patents expiring Jan 2034 may cover CTIM-76; company believes it has defenses but may not prevail.","Amendment reduces development milestones from $55M to $15M, sales milestones from $130M to $12.5M.","Royalty reduced from 8–12% to flat 6% on net sales, starting no sooner than February 2034.","License narrowed to only CTIM-76; company no longer obligated to reimburse Integral for research funding.","Deal includes mutual releases and revised milestone triggers tied to Phase 1b/2, Phase 3, and marketing approvals."],"urls":{"canonical":"https://secwatch.observer/filing/0001842952-24-000005","json":"https://secwatch.observer/filing/0001842952-24-000005.json","markdown":"https://secwatch.observer/filing/0001842952-24-000005.md","text":"https://secwatch.observer/filing/0001842952-24-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842952/000184295224000005/0001842952-24-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842952/000184295224000005/cntx-20240229.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T02:55:22.023851+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4a6c47018fa54081ecaa27e6bf708831b0532a10","claim":"Context Therapeutics Inc. amended Integral License Agreement with Integral Molecular, Inc. (effective 2024-02-29).","evidence_excerpt":"Context Therapeutics Inc. (the “Company”) amended its collaboration and licensing agreement with Integral Molecular, Inc. (“Integral”) (the “Integral License Agreement”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1842952/000184295224000005/0001842952-24-000005-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Integral Molecular, Inc."},{"label":"Effective","value":"2024-02-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}